Impact of immunosuppressive therapy on recurrence of hepatitis C.
about
Identification and Characterization of Broadly Neutralizing Human Monoclonal Antibodies Directed against the E2 Envelope Glycoprotein of Hepatitis C VirusTreatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug TherapyElderly recipients of hepatitis C positive renal allografts can quickly develop liver diseaseTreatment of hepatitis C virus infectionTreatment of chronic hepatitis C in patients with Crohn's disease.Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles.Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus.Treatment of hepatitis B and C after liver transplantation. Part 2, hepatitis C.Mycophenolate mofetil in patients with hepatitis C virus infection.Immunological aspects in late phase of living donor liver transplant patients: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity.Liver transplantation for liver disease caused by hepatitis C virus infection.Antibody immunosuppressive therapy in solid-organ transplant: Part I.Chronic viral hepatitis in kidney transplantation.Hepatitis C recurrence: the Achilles heel of liver transplantation.Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation.Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantation.Overview of immunosuppression in liver transplantation.Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant.MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course.Minimization of immunosuppression with thymoglobuline pre-treatment and HCV recurrence in liver transplantation.Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients.Does cyclosporine inhibit in vivo hepatitis C virus replication?--a pilot study.Impact of steroids on hepatitis C virus replication in vivo and in vitro.Rapid steroid withdrawal in hepatitis C virus-positive kidney transplant recipients.Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation.Transforming growth factor β1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus--induced liver disease.Recurrent hepatitis C virus disease after liver transplantation and concurrent biliary tract complications: poor outcome.Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C.The impact of immunosuppressant therapy on the recurrence of hepatitis C post-liver transplantation.
P2860
Q27490467-A146B5BD-566B-4B34-9819-4766DD5E75C7Q28073100-C1B8CA28-2862-46F3-A9CA-14F58FBDEC97Q30417970-84D23F09-82BE-4209-857C-A97DC89A7055Q34099424-DADF22E5-50C5-4498-A06B-38167CDEDF52Q34178776-E48DD410-BD84-4273-AE4A-93E89A279753Q34232434-0B99A54C-782C-4B2E-A84E-4F1811193361Q34359751-12904683-F56E-48EF-9A81-37BAC8237D0AQ36028318-9F9A59D9-8A27-4B82-9F19-A3D78C063EE0Q36085885-154EA578-4E45-4C6E-8255-5A509924223EQ37243098-CA89F996-FE8A-4E7A-B07D-4B55769F7262Q37396780-D9B5CF50-A0C4-4362-A5A4-DF7B27C35E02Q37691180-01F08022-86A2-41E9-B56E-618EFB36779AQ37833898-CA6F27F2-841E-47D3-9038-40AE5026B92FQ38174194-28260487-D3CF-46C0-9826-7A52881AFADEQ39968802-773D83A7-79C5-499F-8662-3CB3BD6EC685Q42028499-F4D1E24E-CED7-4EFD-B7CB-7BEA0E0890ABQ42555714-ADE2E765-A89E-41B3-AEA0-8EBC23C7EBCDQ42986490-BB54CDFE-37C1-4398-9C40-14E44749BDCEQ42989881-24FFC5D5-28E4-4619-949B-E24542CFFA95Q42991028-518B6C35-C4B5-4B8C-BA51-E3C53DC5399AQ43037856-9EECEE36-8ED2-4130-BD42-B063E06EEFD7Q43038588-2B041A01-6099-41D1-82E8-406CF32BE7A6Q43041106-DDE09195-BA4A-404C-8C3A-D44560D57524Q44963384-4E092B0D-1D4D-42F8-8A54-B6166D2E2745Q45368415-CF1FF813-832F-4B8C-A06F-77D73921A82DQ45368418-A72FDB81-52DB-4A96-8F66-39F485C7D7A6Q45414507-6B70A2EF-B35C-4B62-9646-E637B6962CACQ50575004-5BF189DC-F283-46AD-A70E-11AEE77D78CCQ55692477-25135739-C225-4E5D-8C9F-727E3D2B1713
P2860
Impact of immunosuppressive therapy on recurrence of hepatitis C.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@ast
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@en
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@nl
type
label
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@ast
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@en
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@nl
prefLabel
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@ast
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@en
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@nl
P2860
P356
P1476
Impact of immunosuppressive therapy on recurrence of hepatitis C.
@en
P2093
Gregory T Everson
P2860
P304
P356
10.1053/JLTS.2002.35852
P433
10 Suppl 1
P577
2002-10-01T00:00:00Z